Reduced plasma nisoldipine concentrations phenytoin-treated patients with epilepsy

Epilepsia

Volumn 37, Issue 11, 1996, Pages 1107-1110

  Michelucci, R ^a   Cipolla, G ^b   Passarelli, D ^c   Gatti, G ^b   Ochan, M ^c   Heinig, R ^a,d   Tassinari, C A ^a   Perucca, E ^b  

^a BELLARIA HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c Bayer SpA Italy   (Italy)

^d Clinical Pharmacology Pharmacodynamics (BSP GDD CP Dyn)   (Germany)

Author keywords

Drug interaction; Epilepsy; Nisoldipine; Pharmacokinetics; Phenytoin

Indexed keywords

CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; NISOLDIPINE; PHENYTOIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DETERMINATION; DRUG SCREENING; EPILEPSY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029798966     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb01032.x     Document Type: Article

References (27)

1. Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987;33:139-44.
2. Perucca E, Hedges AM, Makki KA, Ruprah M, Wilson JF, Richens A. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:401-10.
3. Halpert JR, Guengerich FP, Bend JR, et al. Selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 1994;125:163-75.
4. Perucca E, Richens A. Biotransformation. In: Levy RH, Mattson RH, Meldrum B, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:31-50.
5. Von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JJ, Shader RI. Metabolism of drugs by cytochrome P450-3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29(Suppl 1):33-44.
6. Perucca E, Richens A. Reversal by phenytoin of carbamazepine-induced water intoxication: a pharmacokinetic interaction. J Neurol Neurosurg Psychiatry 1980;43:540-5.
7. Giaccone M, Bartoli A, Gatti G, Marchiselli R, Pisani F, Perucca E. Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. Br J Clin Pharmacol 1996;41:575-9.
8. Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ. Concentrations and effects of oral midazolam are greatly reduced in patients on carbamazepine and phenytoin. Epilepsia 1996;37: 253-7.
9. Perucca E, Richens A. Reduction of the oral availability of lignocaine by induction of first pass metabolism in epileptic patients. Br J Clin Pharmacol 1979;8:21-31.
10. Back DJ, Grimmer SFM, Orme MLE, Proudlove C, Mann RD, Breckenridge AM. Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 1988; 25:527-32.
11. Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18:595-606.
12. Guengerich FP, Brian WR, Iwasaki M, et al. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P450IIIA4. J Med Chem 1991;34:1838-44.
13. Regardh CG, Baarnhielm C, Edgar B, Hoffmann KJ. Pharmacokinetics and biotransformation of 1,4-dihydropyridine calcium antagonists. Prog Drug Metab 1990;12:41-86.
14. Schmidt D, Ried S. Clinical relevance of calcium antagonists in the treatment of epilepsy. Arzneimittelforschung 1989;39:156-8.
15. 2+ antagonists in electrocortical shock seizures. Epilepsia 1990;31:68-74.
16. Capewell S, Freestone S, Critchley JAJH, Pottage A, Prescott L. Reduced felodipine bioavailability in patients taking anticonvulsants. Lancet 1988;2:480-2.
17. Tartara A, Galimberti CA, Manni R, et al. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine bioavailability in epileptic patients. Br J Clin Pharmacol 1991;32: 335-40.
18. Friedel HA, Sorkin EM. Nisoldipine: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 1988;36:682-731.
19. Ahr G, Wingender W, Kuhlmann J. Pharmacokinetics of nisoldipine. In: Hugenholtz PG, Meyer J, eds. Nisoldipine. Berlin: Springer, 1987:59-66.
20. Van Harten J, Lodewijks MM, Guyt-Scholten JW, Van Brummelen P, Breimer DD. Gas-chromatographic determination of nisoldipine and one of its metabolites in plasma. J Chromatogr 1987; 423:327-33.
21. Lasseter KC, Shamblen EC, Lettieri J, et al. Dose-proportional pharmacokinetics of nisoldipine in healthy volunteers. Clin Pharmacol Ther 1987;41:234.
22. Endrenyi L. Distribution characteristics of selected kinetic parameters in a population. In: Bozler A, Van Rossum J, eds. Pharmacokinetics during drug developmentt: data analysis and evaluation techniques, Stuttgart: Fischer-Verlag, 1981:27-8.
23. Bailey DG, Arnold JMO, Strong MA, Munoz D, Spence JD. Effects of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 1993;54:589-94.
24. Meikle AW, Jubiz W, Matsukura S, West CD, Tyler FH. Effect of diphenylhydantoin on the metabolism of metyrapone and release of ACTH in man. J Clin Endocrinol 1969;29:1553-8.
25. Fine A, Henderson IR, Morgan DR. Malabsorption of frusemide caused by phenytoin. Br Med J 1977;2:1061-2.
26. Rowland M, Gupta SK. Cyclosporin-phenytoin interaction: reevaluation using metabolite data. Br J Clin Pharmacol 1987;24: 329-34.
27. Van Harten J, Van Brummelen P, Lodewijks MthM, Danhof M, Breimer DD. Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. Clin Pharmacol Ther 1988;43:332-41.